Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023
HOUSTON--(BUSINESS WIRE)--Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, LLC. “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023, in Orlando, FL.
"We look forward to presenting preclinical data on our TEAD inhibitor, which we believe has best-in-class potential based on its optimized TEAD isoform selectivity profile and resultant preclinical activity superior to that of other compounds in development,” said Stephen Rubino, Ph.D., Sporos’ Chief Executive Officer. “SPR1 inhibitors show single-agent activity against multiple TEAD-dependent cell lines in vitro and in vivo, including a range of non-NF2 mutation cell lines and those cell lines that are simply YAP-hyperactive. In addition, our differentiated TEAD inhibitors have demonstrated potent synergistic activity in combination with inhibitors of the MAPK pathway, creating the potential for broad applicability across a number of cancers with serious unmet medical need.”
Presentation Details:
Title: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM - 5:00 PM
Abstract Number: 445
About Sporos BioDiscovery
Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery, Inc. is a wholly-owned affiliate company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.
Contacts
Media and Investor Contact
Lauren Stival Hopfer
lhopfer@sporosbio.com
201.841.6116
Editor Details
-
Company:
- Businesswire
